ARCHIVES

First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors

This article is from The Cancer Letter archive.

Vol. 34 No. 6 | June 24, 2011

Download PDF Visit The Full Archive

Related Articles

Payline Not Set For CCOPs Yet In Recompetition

March 1, 1991

Tobacco Use Research Centers Funded

October 22, 1999

Some NCAB Members Lack Understanding f Bypass Budget’s Value, Purpose

September 1, 1989

Adcetris Granted Approval For Hodgkin’s Lymphoma and ALCL

September 30, 2011

NIH oncology peer reviewers are protesting the outcome of a recent meeting in which their own grant applications fared so poorly that the reviewers said they were penalized for their service.

May 6, 2005

Breast Cancer Coalition Widens Its Agenda For Advocacy, Vows To Fight NIH Cutbacks

May 5, 1995